Work

The value of 18F‑FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation

Year: 2020

Type: article

Abstract: The present study aimed to determine whether 18F‑FDG PET/CT performed before and/or after allogeneic hematopoietic stem cell transplantation (allo‑HSCT) can predict clinical outcomes in acute leukemia (AL). A total of 79 examinations comprising 72 patients with AL who underwent 18F‑FDG PET/CT before and/or after allo‑HSCT were retrospectively enrolled between January 2011 and January 2019. Outcomes were assessed using overall survival (OS) and disease‑free survival (DFS). A total of 63 examinations were PET‑positive, while 16 examinations were PET‑negative. Increased BM and splenic 18F‑FDG uptake were observed in 24 (19/79) and 14% (11/79) of examinations, respectively. 18F‑FDG‑avid lymph nodes were observed in 38% (30/79) of examinations. ENEMES involvement was detected in 44% (35/79) of examinations. The presence of ENEMES involvement [OS hazard ratio (HR), 6.399; 95% confidence interval (CI), 1.843‑22.224; P=0.003; post‑HSCT OS: HR, 7.203; 95% CI, 1.510‑34.369; P=0.013; DFS HR, 3.671; 95% CI, 1.145‑11.768; P=0.029], post‑transplantation minimal residual disease (DFS HR, 4.381; 95% CI, 1.594‑12.040; P=0.004; pre‑HSCT OS HR, 11.455; 95% CI, 1.336‑98.179; P=0.026) and disease status (OS HR, 0.330; 95% CI, 0.128‑0.848; P=0.021; post‑HSCT OS HR, 0.195; 95% CI, 0.050‑0.762; P=0.019; DFS: HR, 0.278; 95% CI, 0.091‑0.851; P=0.025) could serve as an adverse prognostic factor in patients with AL treated with allo‑HSCT. 18F‑FDG PET/CT before and/or after allo‑HSCT was a predictor for OS and DFS in patients with AL. ENEMES involvement detected using 18F‑FDG PET/CT may help identify patients with AL who are likely to have unfavorable clinical outcomes.

Source: Oncology Letters

DOI: 10.3892/ol.2020.12036